REMEGEN (09995) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 2.46%, trading at HK$89.50, with a turnover of HK$151 million.

REMEGEN issued an announcement stating that the company's self-developed Disitamab Vedotin for injection (brand name: Aidixi) has received approval from the National Medical Products Administration for an additional indication. The new approval is for the treatment of breast cancer in a specific patient population, marking the drug's fourth approved indication in China. This further expands the product's clinical application scope.

As one of REMEGEN's core products, the expansion of indications for Disitamab Vedotin will further enrich the company's product portfolio and enhance its core competitiveness. It is reported that the drug was successfully included in the National Reimbursement Drug List through negotiations in 2024, significantly reducing patients' out-of-pocket costs. This has led to a notable increase in prescription volumes, laying a foundation for the market promotion of the new indication.